Abeona Therapeutics Inc. (ABEO) Q3 2026 Earnings Call November 9, 2026 8:30 AM EST
Company Participants
Gregory Gin – Vice President of Investor Relations & Corporate Communications
Vishwas Seshadri – President, CEO & Director
Madhav Vasanthavada – SVP, Chief Commercial Officer & Head of Business Development
Joseph Vazzano – Chief Financial Officer
Conference Call Participants
Mohamad Amin Makarem – Jefferies LLC, Research Division
Raghuram Selvaraju – H.C. Wainwright & Co, LLC, Research Division
Joshua Nickerson – Stifel, Nicolaus & Company, Incorporated, Research Division
Jeffrey Jones – Oppenheimer & Co. Inc., Research Division
Laura Suriel-Suarez – Alliance Global Partners, Research Division
Aaron Welch
Presentation
Operator
Good morning, everyone, and welcome to Abeona Therapeutics 3Q 2026 Conference Call. [Operator Instructions] Please note this conference is being recorded. I will now turn the conference over to your host, Greg Gin, Vice President of Investor Relations and Corporate Communications. Greg, the floor is yours.
Gregory Gin
Vice President of Investor Relations & Corporate Communications
Thank you, Tom. Good morning, and thank you for joining us on our third quarter 2026 results conference call. During this call, we will refer to the press release issued this morning announcing the acquisition of APT-1011 and our third quarter financial results. They are available on our corporate website at www.abeonatherapeutics.com.
Joining me on today’s call are Dr. Vish Seshadri, Chief Executive Officer; Dr. Madhav Vasanthavada, Chief Commercial Officer; Joe Vazzano, Chief Financial Officer; as well as Dr. Brian Kevany, Chief Technical Officer. We will be making projections and forward-looking statements during today’s call, which are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on current expectations and are subject to change. Actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those outlined in our Form 10-K and periodic reports filed with the SEC.